At Caligor Coghlan Pharma Services (CCPS) our Early Access to Medicines (EAM) services are designed with one goal in mind: to expand access to treatment so more people benefit from the impact of innovative medicines. Our EAM team has a background in the clinical trial world and each of or our team members have been part of global orphan and rare disease drug development and global clinical trials. These skills have been transferred over to the unique world of ?Early Access to Treatments?. We have the skills and experience to design, set up and manage these unique programs around the world, providing both the client and physicians with expert support throughout the process. In addition, our Regulatory Affairs and Strategic Services group can assist you with a range of services supporting drug and device development from concept to commercialization.